Literature DB >> 23055415

Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation.

P D Morrison1, J M Stone.   

Abstract

OBJECTIVE: It is unknown if cannabis recreates the negative symptoms of schizophrenia.
METHODS: Healthy male volunteers (n = 22) completed two experimental sessions in which they received intravenous (IV) delta-9-tetrahydrocannabinol (THC) 2.5 mg or placebo in a randomised counterbalanced order. Negative symptoms were rated using the self-reported community assessment of psychic experiences scale (CAPE). Sedation was rated using the mood-adjective check-list (UMACL). Plasma concentrations of THC were measured over the course of the study. Data were analysed by non-parametric tests.
RESULTS: Participants reported an increase in negative symptoms from baseline under THC but not placebo conditions (p < 0.001). Negative symptoms showed no relationship with self-rated sedation or plasma concentrations of THC.
CONCLUSIONS: At plasma concentrations resembling recreational use, THC elicited schizophrenia-like negative symptoms which were not merely attributable to sedation. In the community, negative symptoms may be an adverse effect of cannabis use.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 23055415     DOI: 10.1002/hup.1166

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  12 in total

Review 1.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

2.  The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Authors:  Michelle Carbuto; R Andrew Sewell; Ashley Williams; Kim Forselius-Bielen; Gabriel Braley; Jacqueline Elander; Brian Pittman; Ashley Schnakenberg; Savita Bhakta; Edward Perry; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2011-08-16       Impact factor: 4.530

Review 3.  Drug models of schizophrenia.

Authors:  Hannah Steeds; Robin L Carhart-Harris; James M Stone
Journal:  Ther Adv Psychopharmacol       Date:  2015-02

4.  Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis.

Authors:  Swapnil Gupta; Joao P De Aquino; Deepak C D'Souza; Mohini Ranganathan
Journal:  Psychopharmacology (Berl)       Date:  2019-03-27       Impact factor: 4.530

5.  Impact of cannabis legalization on healthcare utilization for psychosis and schizophrenia in Colorado.

Authors:  George Sam Wang; Christine Buttorff; Asa Wilks; Daniel Schwam; Gregory Tung; Rosalie Liccardo Pacula
Journal:  Int J Drug Policy       Date:  2022-04-22

Review 6.  Cannabis and development of dual diagnoses: A literature review.

Authors:  Rebecca C Hanna; Jessica M Perez; Subroto Ghose
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-09       Impact factor: 3.829

Review 7.  [Clinical prognosis of schizophrenic patients with cannabis addiction. Between nihilism and hope].

Authors:  T Schnell
Journal:  Nervenarzt       Date:  2014-09       Impact factor: 1.214

8.  The Behavioral Sequelae of Cannabis Use in Healthy People: A Systematic Review.

Authors:  Maryam Sorkhou; Rachel H Bedder; Tony P George
Journal:  Front Psychiatry       Date:  2021-02-16       Impact factor: 4.157

Review 9.  Gone to Pot - A Review of the Association between Cannabis and Psychosis.

Authors:  Rajiv Radhakrishnan; Samuel T Wilkinson; Deepak Cyril D'Souza
Journal:  Front Psychiatry       Date:  2014-05-22       Impact factor: 4.157

10.  Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans.

Authors:  Marco Colizzi; Nathalie Weltens; Philip McGuire; Lukas Van Oudenhove; Sagnik Bhattacharyya
Journal:  Brain Sci       Date:  2019-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.